Cardiology

Exercise began as foraging for survival for our hunter/gatherer forbears and is no less essential in our contemporary age of sitting and screen time. Take a quick trip through history.

How prevalent is NAFLD worldwide? What is the preferred treatment? And more questions to test your NAFLD knowledge.

A new study found patients with T1D and T2D had a greater risk for stenotic lesions, whereas risk for valvular regurgitation was lower in those with T2D.

Apple recently announced a new software release that will allow Apple Watch users access to health care-focused features and apps.

ADA 2022: Reduction in risk of progression to type 2 diabetes of 60% was seen in STEP program clinical trial participants with overweight or obesity.

ADA 2022: The protective effect of finerenone on cardiovascular and renal outcomes was not affected by initial HbA1c levels or T2D duration in analysis of data from the FIDELITY pooled cohort.

ADA 2022: Professor Hiddo Heerspink led the prespecified SURPASS-4 analysis that found tirzepatide associated with a 41% reduction in risk of a composite renal outcome.

ADA 2022: In a real-world study of nearly half a million adults with T2D followed for 5 years, the SGLT-2 inhibitor surpassed both other classes used in routine clinical care.

ADA 2022: Tirzepatide, a GIP/GLP-1 receptor agonist, reduced a composite of kidney events in patients with type 2 diabetes and at increased cardiovascular risk in an analysis of SURPASS-4.

The first study of its kind found that intensive blood pressure control may be most beneficial in older adults with life expectancy greater than 3 years vs less than 1 year.

One-half of more than 600 000 patients with ASCVD were not prescribed statins at all and only 22.5% were taking a high intensity statin, according to a recent study.

Lead author of a recent study discusses why clinicians may be hesitant to use TikTok and how social media may shape health care going forward.

Kosiborod, a cardiologist, and Skolnik, a family practitioner, agree no single specialty owns that prescription and that "it takes a village to care for a patient."

Among more than 3000 participants with prediabetes, neither metformin or lifestyle change reduced risk for CV events over 21 years according to Diabetes Prevention Program Outcomes Study investigators.

In adults with type 2 diabetes seen in primary care, lowering glucose substantially during the first 12 months post-diagnosis decreased risk for future MACE.

Mikhail Kosiborod, MD, a cardiologist and Neil Skolnik, MD, a primary care physician, agree that whoever is seeing the patient should prescribe the drug that is needed.

Lead author of a recent study sat down with Patient Care to discuss how clinicians are using the popular video sharing app and the quality of content available.

The patient is a young man who presents after resolution of several hours of chest pain. He is recovering from a lower GI illness and still taking Cipro. What's your Dx?

HbA1c levels over time were found higher at initiation of second-line treatment in veterans aged 55 years and younger, a trend unsettling to a new study's lead author.

New study presented at Heart Rhythm 2022 showed applying AI to an Apple Watch ECG can effectively identify LV dysfunction in a nonclinical setting.

Initiation of second-line type 2 diabetes treatment is lagging while A1c at the time it is introduced is climbing. The author of a new study highlights his findings on clinical inertia.

Seven risk factors accounted for 85% of the risk of first acute myocardial infarction in young adults in a new study.

High-level results show the trial met its composite primary endpoint, lowering risk of CV death or worsening disease in patients with HFmrEF/HFpEF.

Black patients hospitalized with atrial fibrillation were 25% less likely to receive oral anticoagulants upon discharge according to a large national registry study.

PCPs and internists accounted nationally for 57% of SGLT2i and 52% of GLP1RA prescriptions in 2020, more than any other specialty, according to new research.